Bracamonte-Baran William, Kim Sang T
Department of Rheumatology, Allergy & Immunology, Yale University, 300 Cedar Street, TAC S541, New Haven, CT 06520, USA.
Department of Rheumatology, Allergy & Immunology, Yale University, 300 Cedar Street, TAC S541, New Haven, CT 06520, USA.
Immunol Allergy Clin North Am. 2025 May;45(2):223-249. doi: 10.1016/j.iac.2025.01.010.
With their groundbreaking clinical responses, immune checkpoint inhibitors (ICIs) have ushered in a new chapter in cancer therapeutics. However, they are often associated with life-threatening or organ-threatening autoimmune/autoinflammatory phenomena, collectively termed immune-related adverse events (irAEs). In this review, we will first describe the mechanisms of action of ICIs as well as irAEs. Next, we will review biomarkers for predicting the development of irAEs or stratifying risks.
免疫检查点抑制剂（ICIs）凭借其开创性的临床反应，开启了癌症治疗的新篇章。然而，它们常常与危及生命或器官的自身免疫/自身炎症现象相关联，这些现象统称为免疫相关不良事件（irAEs）。在本综述中，我们将首先描述ICIs的作用机制以及irAEs。接下来，我们将综述用于预测irAEs发生或分层风险的生物标志物。
